A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT04929249
- Phase
- PHASE3
- Status
- Completed
Conditions
- Atherosclerotic Cardiovascular Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Inclisiran — DRUGInclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Study Details
The purpose of this study was to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with maximally tolerated statin therapy alone) compared to usual care in an atherosclerotic cardiovascular disease (ASCVD) population.
Key Dates
- Start date
- Jun 25, 2021
- Status verified
- May 2025
- Primary completion
- Sep 15, 2023
- Completion
- Sep 15, 2023
Study Design
- Enrollment
- 450 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Inclisiran FirstInclisiran sodium 300 mg 1.5 ml (equivalent to 284 mg of inclisiran) + usual care
- No Intervention: Usual CareTreating physicians were recommended to treat patients in accordance with the 2018 ACC/AHA guidelines
Primary Outcome Measure
Percent Change From Baseline in LDL-C [ Time Frame: Baseline, Day 330 ]
Locations (43)
Find similar trials in Little Rock, AR
By research site
ARcare Center for Clinical Research· Little Rock, ARARcare Center for Clinical Research .· Little Rock, ARKeck Medical Center USC .· Los Angeles, CAd-b-a Greenwich Cardio Assoc CLCZ696BUS08· Greenwich, CTCardiology Ass of Fairfield County .· Stamford, CTIntegrative Research Associates Inc· Fort Lauderdale, FL
Related Studies
- The Prevent Coronary Artery Disease TrialPHASE3 · Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York
- Pelacarsen Roll-over Extension ProgramPHASE3 · Recruiting · Novartis Pharmaceuticals · Birmingham, Alabama
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityPHASE3 · Recruiting · Amgen · Daphne, Alabama
- Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFENot Yet Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee